Bruker Corporation (BRKR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Bruker Corporation stock (BRKR) is currently trading at $35.80. Bruker Corporation PS ratio (Price-to-Sales) is 1.59. Analyst consensus price target for BRKR is $48.43. WallStSmart rates BRKR as Sell.
- BRKR PE ratio analysis and historical PE chart
- BRKR PS ratio (Price-to-Sales) history and trend
- BRKR intrinsic value — DCF, Graham Number, EPV models
- BRKR stock price prediction 2025 2026 2027 2028 2029 2030
- BRKR fair value vs current price
- BRKR insider transactions and insider buying
- Is BRKR undervalued or overvalued?
- Bruker Corporation financial analysis — revenue, earnings, cash flow
- BRKR Piotroski F-Score and Altman Z-Score
- BRKR analyst price target and Smart Rating
Bruker Corporation
📊 No data available
Try selecting a different time range
Smart Analysis
Bruker Corporation (BRKR) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, institutional own.. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Bruker Corporation (BRKR) Key Strengths (3)
92.38% of shares held by major funds and institutions
Paying $1.59 for every $1 of annual revenue
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Bruker Corporation (BRKR) Areas to Watch (7)
Company is destroying shareholder value
Revenue declining -0.20%, a shrinking business
Company is losing money with a negative profit margin
Very thin margins with limited operational efficiency
Modest earnings growth at 8.50%
Growth is fairly priced, not cheap, not expensive
Fairly priced relative to book value
Bruker Corporation (BRKR) Detailed Analysis Report
Overall Assessment
This company scores 42/100 in our Smart Analysis, earning a D grade. Out of 10 metrics analyzed, 3 register as strengths (avg 8.3/10) while 7 fall into concern territory (avg 2.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Sales, Market Cap. Valuation metrics including Price/Sales (1.59) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Profit Margin. Some valuation metrics including PEG Ratio (1.52), Price/Book (2.07) suggest expensive pricing. Growth concerns include Revenue Growth at -0.20%, EPS Growth at 8.50%, which may limit upside. Profitability pressure is visible in Return on Equity at -0.38%, Operating Margin at 6.58%, Profit Margin at -0.25%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -0.38% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -0.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BRKR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BRKR's Price-to-Sales ratio of 1.59x trades 29% below its historical average of 2.22x (26th percentile). The current valuation is 65% below its historical high of 4.52x set in Dec 2007, and 188% above its historical low of 0.55x in Jan 2009. Over the past 12 months, the PS ratio has compressed from ~1.8x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Bruker Corporation (BRKR) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Bruker Corporation is in a turnaround phase, with management focused on restoring profitability. Revenue reached 3.4B with 20% decline year-over-year. The company is currently unprofitable, posting a -25.0% profit margin.
Key Findings
Generating 207M in free cash flow and 230M in operating cash flow. Earnings are translating into actual cash generation.
Revenue contracted 20% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -25.0% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Debt management: total debt of 1.9B is significantly higher than cash (299M). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Bruker Corporation.
Bottom Line
Bruker Corporation is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(32 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:27:45 AM
About Bruker Corporation(BRKR)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Bruker Corporation develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions in the United States, Europe, Asia Pacific, and internationally. The company is headquartered in Billerica, Massachusetts.